DWK-1339 is an inhibitor of amyloid-β (Aβ) aggregation.{35159} It inhibits aggregation of monomeric Aβ (1-42) (Aβ42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 µM. DWK-1339 (10 µM) reduces Aβ42
英文名:
MDR-1339
库存:
1 mg, 5 mg, 500 µg
供应商:
Cayman
CAS号:
1018946-38-7
An inhibitor of amyloid-β aggregation; inhibits aggregation of monomeric Aβ42 and induces disaggregation of Aβ42 fibrils in vitro from 3.1-50 µM; reduces Aβ42-induced toxicity in HT22 cells at 10 µM; increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer's disease at 10 mg/kg; decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer's disease